Caris Life Sciences and Syapse to collaborate on genomic information

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Caris Life Sciences and Syapse will collaborate to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network.

Integration of Caris Molecular Intelligence, Caris’ panomic, comprehensive tumor profiling service, with the Syapse Precision Medicine Platform , will provide a powerful real-time, point-of-care, clinical decision support system to enable more informed treatment decisions for each individual patient. Participating COE Network sites can use the integrated decision support system, and may use Syapse to further support their complete precision medicine workflows.

Caris Molecular Intelligence uses multiple technology platforms, including a proprietary 592-gene Next-Generation Sequencing panel with full gene coverage to assess point mutations, indels, and copy number variations, alongside RNAseq, for select gene fusions, in addition to Immunohistochemistry, in situ hybridization, and other platforms.

“We expect to profile 50,000 to 100,000 cancer patients annually across the COE Network. This is the largest oncology focused effort to combine comprehensive genomic and molecular profiling information with clinical outcomes data,” said David Halbert, chairman and CEO of Caris Life Sciences.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login